EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Association of Body Mass Index with SARS ‐ CoV ‐2 Infection in Inflammatory Arthritis Patients Receiving Biologic Therapy: Singapore National Biologics Register Findings

Preeti Dhanasekaran iD, Siaw Ing Yeo, Yi Xin Ng, Rosa Lim, Stephanie Wong, Stanley Angkodjojo, Andrew Yu Keat Khor, Li Wearn Koh, Manjari Lahiri iD, Margaret Ma

International Journal of Rheumatic Diseases · 2026-06 · 29 (6)

DOI: 10.1111/1756-185x.70682 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 15.06.2026. Verfasst von Preeti Dhanasekaran und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Arthritis, Rheumatoid, Biological Products. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chapter of Rheumatologists, Academy of Medicine, Singapore.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To determine the association of body mass index (BMI) with incident COVID‐19 infection in patients with inflammatory arthritis (IA) using biologic disease‐modifying anti‐rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) and to describe characteristics of patients with severe COVID‐19 infection.

Methods

This prospective inception cohort study included IA patients ≥ 21 years old initiating a bDMARD after July 2016 across five public hospitals in Singapore. Data were collected via questionnaires and electronic medical records. Baseline characteristics were compared between patients who developed COVID‐19 and those who did not. The association between BMI and time to incident COVID‐19 infection was assessed using Cox proportional hazards regression, adjusting for demographic and clinical factors.

Results

Five hundred sixty‐one patients (60.1% female, 69.0% Chinese; median age 49.0 years) were included. Diagnoses included rheumatoid arthritis (39.6%), psoriatic arthritis (26.6%), and spondyloarthritides (33.9%). Most (63.8%) were on tumor necrosis factor (TNF) inhibitors. SARS‐CoV‐2 infection occurred in 140 (25.0%) patients. Those infected had higher BMI (27.0 vs. 25.0 kg/m 2 , p = 0.005). BMI ≥ 23 kg/m 2 was independently associated with increased risk of infection (HR 1.63 [95% CI 1.05, 2.53]; p = 0.029). Severe COVID‐19 infection occurred in five patients. All were male, and four had underlying comorbidities. The underlying rheumatic diagnoses included rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. These patients were receiving b/tsDMARDs including golimumab, tofacitinib, adalimumab biosimilar (Amgevita), and infliximab biosimilar (Remsima). Importantly, no deaths were reported.

Conclusion

Being overweight or obese (BMI ≥ 23 kg/m 2 ) was independently associated with higher COVID‐19 infection risk. Severe infections were rare.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritisArthritis, RheumatoidBiological ProductsBody Mass IndexCOVID-19ObesityAdultFemaleHumansMaleMiddle AgedIncidenceProspective StudiesRegistriesRisk AssessmentRisk FactorsSARS-CoV-2Singapore

Stichwörter der Autor:innen

COVID‐19SARS‐CoV‐2arthritisbiologic therapybody mass indexinflammatory arthritisregistry

Substanzen

Antirheumatic AgentsBiological Products

Autor:innen und Institutionen

  • Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore.
  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore.
  • Department of Medicine, Sengkang General Hospital, Singapore, Singapore.
  • Division of Rheumatology, Changi General Hospital, Singapore, Singapore.

ORCID-Profile: Preeti Dhanasekaran, Manjari Lahiri

Förderung

  • Chapter of Rheumatologists, Academy of Medicine, Singapore

Zitieren

APA

Dhanasekaran, P., Yeo, S. I., Ng, Y. X., Lim, R., Wong, S., Angkodjojo, S., Khor, A. Y. K., Koh, L. W., Lahiri, M., & Ma, M. (2026). Association of Body Mass Index with SARS ‐ CoV ‐2 Infection in Inflammatory Arthritis Patients Receiving Biologic Therapy: Singapore National Biologics Register Findings. International Journal of Rheumatic Diseases, 29(6). https://doi.org/10.1111/1756-185x.70682

Vancouver

Dhanasekaran P, Yeo SI, Ng YX, Lim R, Wong S, Angkodjojo S, et al. Association of Body Mass Index with SARS ‐ CoV ‐2 Infection in Inflammatory Arthritis Patients Receiving Biologic Therapy: Singapore National Biologics Register Findings. International Journal of Rheumatic Diseases. 2026;29(6). doi:10.1111/1756-185x.70682

BibTeX
@article{Dhanasekaran2026,
  author = {Dhanasekaran, Preeti and Yeo, Siaw Ing and Ng, Yi Xin and Lim, Rosa and Wong, Stephanie and Angkodjojo, Stanley and Khor, Andrew Yu Keat and Koh, Li Wearn and Lahiri, Manjari and Ma, Margaret},
  title = {Association of Body Mass Index with SARS ‐ CoV ‐2 Infection in Inflammatory Arthritis Patients Receiving Biologic Therapy: Singapore National Biologics Register Findings},
  journal = {International Journal of Rheumatic Diseases},
  year = {2026},
  volume = {29},
  number = {6},
  doi = {10.1111/1756-185x.70682}
}
Kostenlos starten →